Clinical value of combined detection of serum ProGRP, CEA, CYFRA211, NSE, CA199 and AFP in diagnosis of lung cancer

Objective To compare the expression of T-cad protein in superficial bladder carcinoma and study the evaluation in diagnosis and follow-up. Methods Urine were collected from 50 cases with superficial bladder transitional cell carcinoma (TCC) and other 50 controls. T-cad protein levels in the urine of these cases were measured. The 50 superficial bladder TCC cases were received regular bladder perfusion chemotherapy and cystoscopy examination after transurethral resection of bladder tumor. T-cad expression levels in the tissues were examined by immunohistochemical staining, and their correlation with clinicopathologic parameters (e.g. G grade and recrudescence) were analyzed. Results The average urine T-cad concentration was (2.12±1.16) ng/ml in bladder TCC group, and was (3.03±1.97) ng/ml in the control group. There was no significant difference between them (P=0.08). Five cases (29.4%) had low or no expression of T-cad protein in the tissue of 17 patients with G1 superficial bladder TCC. Seventeen cases (51.5%) had low or no expression of T-cad protein in the tissue of 33 patients with G2-G3 superficial bladder TCC. The expression of T-cad in G1 was higher than that in G2-G3, and the difference was significant (P < 0.05). Recurrence rate was 17.9% in 28 bladder cancer patients with high T-cad expression, and was 54.5% in 22 bladder cancer patients with low T-cad expression. There was a significant difference between the two groups (P < 0.05). Conclusions Decreased T-cad expression in the tissue of bladder TCC was negatively correlated with high grade and tumor relapse, and may be associated with malignancy of bladder TCC. Key words: Superficial bladder cancer; T-cadherin